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Abstract  
In this study calendering is used as a downstream technique to shape monolithic co-extruded 
fixed-dose combination products in a continuous way. Co-extrudates with a metoprolol tartrate-
loaded sustained-release core and a hydrochlorothiazide-loaded immediate-release coat were 
produced and immediately shaped into a monolithic drug delivery system via calendering, 
using chilled rolls with tablet-shaped cavities. In vitro metoprolol tartrate release from the 
ethylcellulose core of the calendered tablets was prolonged in comparison to the sustained 
release of a multiparticulate dosage form, prepared manually by cutting co-extrudates into 
mini-matrices. Analysis of the dosage forms using X-ray micro-computed tomography only 
detected small differences between the pore structure of the core of the calendered tablet and 
the mini-matrices. Diffusion path length was shown to be the main mechanism behind the 
release kinetics. Terahertz pulsed imaging visualized that adhesion between the core and coat 
of the calendered tablet was not complete and a gradient in coat thickness (varying from 200 
to 600 µm) was observed. Modulated differential scanning calorimetry and X-ray diffraction 
indicated that the solid state properties of both drugs were not affected by the calendering 
procedure.  
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List of abbreviations  
HME   Hot-melt extrusion 
FDC   Fixed-dose combination 
MPT   Metoprolol tartrate 
HCT   Hydrochlorothiazide 
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PEO   Polyethylene oxide 
PEG   Polyethylene glycol 
MDSC   Modulated differential scanning calorimetry 
XRD   X-ray diffraction 
DBS   Dibutyl sebacate 
MW   Molecular weight 
USP   United States Pharmacopeia 
UV    Ultraviolet 
Tg    Glass transition temperature 
RCS   Refrigerated cooling system 
TPI    Terahertz pulsed imaging 
Micro-CT  Micro-computed tomography 
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1. INTRODUCTION 
In co-extrusion two or more formulations are simultaneously processed via hot-melt 1 
extrusion (HME) through the same die. In addition to the advantages of HME, such as the 2 
continuity of the production process, not requiring the use of solvents or water and improving 3 
drug bioavailability, this technique offers the opportunity to produce fixed-dose combination 4 
(FDC) products with enhanced release characteristics, by making it possible to design 5 
multilayered dosage forms that are extruded in the same process step, in order to modulate 6 
the drug release from each layer. Although co-extrusion is used to manufacture implants [1] 7 
and vaginal rings [2], there are currently no co-extruded dosage forms for oral application on 8 
the market. In literature only a limited number of studies describe co-extrusion of dosage forms 9 
for oral drug delivery [3-6]. Recently co-extrusion has been used for the development of 10 
multiparticulate fixed-dose combination drug products for oral pharmaceutical application, 11 
consisting of a controlled release core matrix and an immediate release coat [7] and to develop 12 
sustained and dual drug release formulations for individual dosing [8]. For pharmaceutical 13 
applications of co-extrusion, one of the major challenges is the shaping of the final product in 14 
a continuous way, as a suitable downstream shaping technique is needed to ensure an efficient 15 
manufacturing line. Previously injection-molding has been used to shape extrudates into solid 16 
oral dosage forms in a semi-continuous way [9, 10] and even to prepare co-injection moulded 17 
matrices [4]. Calendering is a technique that allows in-line shaping of the extruded material in 18 
a fully continuous single-step process. Using this technique the freshly-extruded thermoplastic 19 
strand is guided through a pair of temperature-controlled rolls containing tablet- or pill-shaped 20 
cavities, yielding bands that contain single tablet-shaped cores of the desired shape. Although 21 
this technique is already widely established in the plastic and confectionary industry to produce 22 
monolithic shapes, only the Meltrex® technology [11] and the continuous extrusion process for 23 
the production of sustained release tablets developed by Knoll AG [12] report calendering as 24 
a possible shaping tool for pharmaceutical applications.  25 
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In this study the use of calendering to continuously shape a multi-layered co-extrudate into 26 
a monolithic FDC dosage form was evaluated. In the treatment of cardiovascular disease the 27 
FDC of the beta-blocker metoprolol tartrate (MPT) with the diuretic hydrochlorothiazide (HCT) 28 
is well established [13]. Therefore co-extrudates consisting of a plasticized ethylcellulose (EC) 29 
core, containing MPT and polyethylene oxide (PEO), and a coat of polyethylene oxide (PEO) 30 
/ polyethylene glycol (PEG) containing HCT were previously developed [14]. After production 31 
the cylindrical co-extrudate with concentric coat layer was immediately shaped via calendering, 32 
using chilled rolls with tablet-shaped cavities. In this way monolithic dosage forms with a 33 
sustained-release core, loaded with MPT as model drug, and an immediate-release coat, 34 
loaded with HCT as model drug, were produced and evaluated for in vitro drug release, coat 35 
thickness and uniformity and pore structure. The impact of the calendering step on the physical 36 
state of the drugs in the formulations was characterized using modulated differential scanning 37 
calorimetry (MDSC) and X-ray diffraction (XRD).   38 
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2. MATERIALS AND METHODS 39 
2.1 Materials 40 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) and hydrochlorothiazide 41 
(HCT) (Utag, Amsterdam, the Netherlands) were used as sustained and immediate release 42 
model drugs, respectively. As excipients ethylcellulose (Ethocel® std 10, Colorcon, Dartford 43 
Kent, United Kingdom), dibutyl sebacate (DBS) (Sigma-Aldrich, Bornem, Belgium), 44 
polyethylene oxide (PEO) 1M (MW: 1000000 g/mol, SentryTM Polyox® WSR N12K, Colorcon, 45 
Dartford Kent, United Kingdom), PEO 100K (MW: 100000 g/mol, SentryTM Polyox® WSR N10, 46 
Colorcon, Dartford Kent, United Kingdom) and polyethylene glycol (PEG) 4K (MW: 4000 g/mol, 47 
Fagron, Waregem, Belgium) were used.  All other chemicals were of analytical grade. 48 
2.2 Methods 49 
2.2.1 Co-extrusion 50 
Co-extrusion was carried out using two co-rotating Prism Eurolab 16 mm twin-screw 51 
extruders (ThermoFisher Scientific, Karlsruhe, Germany), connected to a co-extrusion die 52 
(Guill, West Warwick, USA). In the calendering set-up the co-extrusion die was adapted to fit 53 
the diameter of the co-extrudate with the dimensions of the calender cavities, shaping a 54 
cylindrical co-extrudate consisting of a core with a diameter of 4 mm and a concentric coat with 55 
a thickness of 2 mm. To produce the multiparticulates, a cylindrical co-extrudate with an inner 56 
diameter of 3 mm and an outer diameter of 4 mm was manufactured. The heating zones of 57 
both extruders were heated to 80/90/100/100/100/100 °C from feed opening to die-end. The 58 
co-extrusion die was heated to 100 °C. Both premixes were fed separately into an extruder by 59 
a Brabender Flexwall® loss-in-weight powder feeder (Brabender, Duisburg, Germany) at a feed 60 
rate of 200 g/h for the coat and 300 g/h for the core material. A screw speed of 40 rpm and 61 
150 rpm was used for the extruder producing the outer layer and the inner layer, respectively.  62 
2.2.2 Downstream processing 63 
Calendering was performed with a Collin 60 mm calender (Dr. Collin, Ebersberg, 64 
Germany), coupled to a compressed air supply and a Coolenergy chiller (Plastima, Breda, The 65 
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Netherlands), which cooled the calender rolls to a temperature within the range of 4-8 °C. The 66 
speed of the calender rolls was set at 1.5 rpm. Immediately after leaving the co-extrusion die 67 
the co-extruded strand was guided between a pair of chilled pressurized rolls that contained 68 
tablet-shaped cavities, yielding tablets with a diameter of 8 mm and a thickness of 5 mm.  69 
To test the effect of cooling on the MPT release a core extrudate was prepared using the 70 
same process parameters as for the core in the co-extrudate. Part of this material was cooled 71 
at room temperature, while the remaining part was quench-cooled by dipping the core 72 
extrudate in liquid nitrogen immediately after extrusion. 73 
Multiparticulates were obtained by manually cutting a cylindrical co-extrudate with an inner 74 
diameter of 3 mm and an outer diameter of 4 mm into mini-matrices of 2 mm length after 75 
cooling the co-extruded rod to room temperature. 76 
2.2.3 In vitro drug release 77 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 78 
apparatus 1 (baskets) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 79 
Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 80 
Brunswick, New Jersey, USA). The temperature of the dissolution medium (900 ml) was kept 81 
at 37 ± 0.5 °C and the rotational speed of the baskets was set to 100 rpm. For the first hour a 82 
0.1 N solution of hydrochloric acid (pH 1) was used as the dissolution medium. Afterwards the 83 
baskets containing the mini-matrices or tablets were transferred to vessels filled with 84 
phosphate buffer pH 6.8 (USP) as the dissolution medium. Samples (filtered using Distek 45 85 
µm filters) of 5 ml were withdrawn at 5, 10, 15, 20, 30, 45 and 60 minutes for the determination 86 
of HCT concentration in the first dissolution medium and at 1, 2, 4, 6, 8, 12, 16, 20 and 24 87 
hours for the determination of MPT concentration in the second dissolution medium. The core 88 
layer was analyzed separately to cover for the MPT release during the first hour. Samples were 89 
analyzed spectrophotometrically at 316.6 and 222.0 nm, using a UV-spectrophotometer, type 90 
UV-1800 (Shimadzu, Deurne, Belgium) and applying an appropriate calibration curve for 91 
quantification of HCT and MPT, respectively. Each experiment was performed in triplicate.  92 
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2.2.4 Modulated differential scanning calorimetry 93 
The solubility of HCT in the coat of the tablet was studied by cyclic heating of an 94 
oversaturated sample, containing 70 % HCT, followed by annealing at a different temperature 95 
for each cycle in order to reach the maximum solubility at each temperature. After the 96 
annealing step the sample was quenched and heated again to determine the glass transition 97 
temperature (Tg). These cycles were performed for different annealing temperatures in 98 
between the melting point of polymer matrix and drug, and the shift in Tg was monitored using 99 
a differential scanning calorimeter Q200, equipped with a refrigerated cooling system (RCS) 100 
(TA Instruments, Leatherhead, UK). Nitrogen was used as purge gas through the DSC cell (50 101 
ml/min) and the RCS unit (300 ml/min). Samples (± 3 mg) were run in an open aluminum pan 102 
with an underlying heating rate of 5 °C/min. The modulation period and amplitude were set at 103 
50 s and 0.663 °C, respectively (heat-only method). Temperature and enthalpy calibration was 104 
performed with an indium standard at the same scan rate and with the same kind of pans used 105 
in the experiment. MDSC data were analyzed using the TA instruments Universal Analysis 106 
2000 V4.7A software.  107 
2.2.5 X-ray diffraction 108 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 109 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 diffractor 110 
with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage of 40 mV in 111 
the angular range (2θ) varying from 10 to 60° using a step scan mode with a step size of 0.02° 112 
and a measuring time of 1 s/step. 113 
2.2.6 Terahertz pulsed imaging (TPI) 114 
The calendered tablets from different formulations were analyzed using a TPI imaga2000 115 
coating scan system (Teraview, Cambridge, UK). The operation of this system was previously 116 
described by Zeitler et al. [15]. Images were acquired in a point-to-point mode with a step size 117 
of 200 µm. Images were analyzed using TPI View (version 3.0.3, Teraview, Cambridge, UK). 118 
A six-axis robot arm was used to produce a surface map of the calendered tablet. The 119 
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refractive index of the coating material was estimated to be 1.5, based on the surface 120 
reflectivity of the calendered tablets as well as by calibration using the X-ray micro-computed 121 
tomography. Given the very smooth texture of the surface this was deemed to represent an 122 
appropriate measurement for the refractive index as no surface scattering would contribute to 123 
the losses. Using this value histograms and maps of coating uniformity were plotted using 124 
Matlab (R2013a, The Mathworks, Natick MA, USA). 125 
 126 
2.2.7 X-ray micro-computed tomography (Micro-CT) 127 
The porosity of the mini-matrices and tablets was evaluated by means of micro-CT. Co-128 
extruded mini-matrices and calendered tablets were scanned using a Skyscan 1172 high 129 
resolution X-ray micro-CT system (Bruker microCT, Kontich, Belgium), operated at 59 kV 130 
source voltage, with an image pixel size of 1.37 µm and 4.53 µm, for the mini-matrix and the 131 
tablet, respectively. The scanning system is equipped with an aluminum 0.5 mm filter and an 132 
11 Mp CCD detector. For the scan with the image pixel size of 4.53 µm the samples were 133 
rotated over 0.4 ° steps, exposure time was 1000 ms and total scan duration was 42 min. For 134 
the high resolution offset-scan the samples were rotated over 0.2 ° steps, exposure time was 135 
2350 ms, frame averaging was 5 and total scan duration was 9 h 17 min. The images were 136 
reconstructed with NRecon (Version 1.6.3.2, Bruker microCT, Kontich, Belgium) on a GPU-137 
ReconServer. A Gaussian smoothing kernel of 2 pixels was applied, resulting in an 8-bit bitmap 138 
(BMP) image with a linear X-ray attenuation coefficient, displayed as a grey scale value 139 
calibrated between 0 and 255. To compare both dosage forms at the same pixel size, the 140 
images of the mini-matrix system were resized fourfold prior to analysis. Data analysis and 141 
visualization was done with CTAn software (version 1.13.5.1, Bruker microCT, Kontich, 142 
Belgium) and CTVol (version 2.2, Bruker microCT, Kontich, Belgium) for surface rendering. 143 
For image analysis the core was defined as the region of interest (ROI). To this end, applying 144 
a Gaussian blur by 2 pixels allowed separating the two peaks in the grey scale histogram with 145 
a threshold of 34. Pixels with lower intensities were assigned to the core and pixels with a 146 
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higher intensity were assigned to the coat layer. This ROI is applied to the original grey scale 147 
images, in this way removing the coat. Greyscale images were binarised using an Otsu-148 
algorithm, one of the most popular techniques of automatic thresholding [16]. 3D objects 149 
smaller than 20 voxels were considered to be noise and were filtered out of the image used 150 
for porosity analysis. A distinction is made between internal pores, which are located in the 151 
core of the co-extrudate, and pores at the interface between core and coat. The percentage of 152 
internal pores is quantified as the ratio between the internal pore volume in the core and the 153 
object volume (i.e. total volume of solid core material, excluding pores). The percentage of 154 
pores at the interface between both layers is defined as the ratio between the pore volume at 155 
the interface and the total core volume (i.e. region of interest volume, including pores). A size 156 
distribution of the pores is illustrates the percentage of pores in a certain range of structure 157 
thickness. Local structure thickness for a point in solid material is defined by Hildebrand and 158 
Ruegsegger as the diameter of the largest sphere that encloses the point and is entirely 159 
enclosed within the solid surfaces [17]. 160 
  161 
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3. RESULTS AND DISCUSSION 162 
In order to continuously shape a multi-layered co-extrudate into a final monolithic FDC 163 
tablet dosage form the co-extrusion line was extended downstream with a calender and chiller. 164 
Although calendering has been used previously to shape an extrudate into a final dosage form 165 
[11, 12], to our knowledge this study is the first to evaluate calendering as a downstream tool 166 
in a co-extrusion process, thus producing a dosage form with an outer layer that is surrounding 167 
the inner core. In order to evaluate the effect of calendering on the release profiles of two 168 
model drugs, formulations with a MPT-loaded sustained release core and a HCT-loaded 169 
immediate release coat were used (Table 1): the two core formulations A and B varied in their 170 
EC/PEO ratio while a lower MPT content was used in formulation C. This allowed to evaluate 171 
the effect of calendering as a function of the concentration of PEO (added as hydrophilic 172 
additive) and the MPT load [14]. The composition of the coat formulation was constant, except 173 
for the HCT load of formulation C that was adjusted in order to respect the same MPT/HCT 174 
ratio in each of the co-extruded formulations. The MPT-loaded plasticized EC matrix (with the 175 
addition of PEO 1M as a hydrophilic additive) was co-extruded with its HCT-loaded PEO 176 
100K/PEG 4K coat at a temperature of 100 °C. The inserts of the co-extrusion die were 177 
adapted to match the dimensions of the co-extrudate with the dimensions of the calender 178 
cavities. The co-extruded string was guided between the chilled calender rolls to shape a string 179 
of tablets. Calendered tablets were regular in shape and had a uniform aspect as long as the 180 
calender rolls were chilled at 4 ± 1 °C. When the chiller did not succeed in adequately cooling 181 
the calender rolls (i.e. using a chill water temperature > 6°C), the calendered tablets deformed 182 
when the calendered string detached from the chill rolls. As aspect defects were found to be 183 
highly dependent on calender speed and temperature, a low calender speed was used to allow 184 
adequate cooling and perfect shaping of the calendered tablets [18]. The cooling rate of the 185 
material between the calender rolls seemed essential to obtain a dosage form with good shape 186 
and uniform dimensions (Fig. 1). Although minimized by adjusting the die dimensions to the 187 
dimensions of the calender cavities, waste material was created at the sides of the tablets 188 
when forcing the co-extruded strand in between the calender rolls. The amount of waste was 189 
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7.5 % w/w of the total weight of the co-extruded calendered material. As this waste at the 190 
edges of the tablets must be removed to obtain the final dosage forms, this is especially a 191 
disadvantage when working with highly valuable active ingredients. Based on the drug content 192 
of the waste material, it was assessed that it is mainly composed of coat material (93 % of the 193 
total waste fraction), while only a minor part of core material is lost during calendering. This 194 
should be taken into account as this yields tablets with a higher MPT/HCT ratio than 195 
theoretically anticipated based on coat and core composition. The higher MPT/HCT ratio was 196 
confirmed by quantification of the MPT and HCT concentration in the calendered tablets: a 197 
ratio of 8.58 vs. 8.00 based on the composition of coat and core layer. Since TPI was previously 198 
used for the non-destructive analysis of coated tablets [19] this technique was used to visualize 199 
the coat layer and to study the adhesion between core and coat. Especially interesting for the 200 
analysis of calendered tablets via TPI is the fact that not only the thickness of the coat layer, 201 
but also the uniformity and integrity of the coat can be analysed, since penetration depths into 202 
typical pharmaceutical formulations between 1 and 3 mm can currently be achieved [14]. The 203 
thickness of the coat layer varied between 200 and 600 µm (Fig. 2). In the false-colour images 204 
of the tablets of formulation B, a thickness gradient in the coat layer is observed (Fig. 2), which 205 
is more pronounced at the top face compared to the bottom face of the calendered tablets. 206 
This gradient can be explained by the sequenced contact of different regions of the tablet with 207 
the calender rolls. The cross section images based on the micro-CT data from a string of 208 
tablets confirmed this by revealing a recurrent pattern of the thinner area in the coating layer 209 
(Fig. 3). The analysis of the calendered tablet via TPI also clearly identified that the adhesion 210 
between core and coat was not complete as an air gap at the interface between both extruded 211 
layers was detected (Fig. 2). The incomplete adhesion was also confirmed by micro-CT (Fig. 212 
3) and quantified as the percentage of pores at the intersection of core and coat. These pores 213 
at the intersection of core and coat for calendered tablets (2.37 %) were also found for the 214 
multiparticulates (2.06 %), indicating that the incomplete adhesion between coat and core was 215 
not linked to the calendering step in the process, but originated during the co-extrudate 216 
formation. These air pockets could become entrapped between coat and core layer when both 217 
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extrusion flows merge. The air gap between the coating and the core is unlikely to have any 218 
influence on the release characteristics for a tablet with an immediate release coat (as 219 
manufactured in this study) since the coat will rapidly dissolve and expose the core to the 220 
dissolution medium. However, the results show that calendering as a post-processing step for 221 
co-extruded formulations needs further optimization for drug delivery systems where the coat 222 
controls the release of the core, as the differences in thickness of the coating layer and 223 
incomplete adhesion between both layers observed in this study would induce significant 224 
variability in the release rate. Moreover, for those types of systems it will be challenging to 225 
obtain a coat that completely seals the core, a feat that is difficult to achieve with the 226 
calendering set-up used in this study, especially at the edges of the calendered tablets (Fig. 227 
3).  228 
Physico-chemical characterisation of MPT and HCT in core and coat, respectively, was 229 
performed in order to evaluate the effect of calendering on the physical state of the 230 
incorporated drug substances. The solubility of HCT in the PEO/PEG carrier was determined 231 
by monitoring the shift in Tg after annealing a supersaturated physical mixture at different 232 
temperatures and subsequent quenching. First of all the Gordon-Taylor curve was established 233 
for different mixtures of HCT in the PEO/PEG carrier. The composition dependence of the 234 
glass transition temperature was fitted by the usual Gordon-Taylor law [20, 21]: 235 
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In equation 1 Tg(HCT) and Tg(carrier) are respectively the glass transition temperature of pure 237 
HCT and the carrier, X(HCT) is the HCT fraction in the mixture, and K is a fitting parameter 238 
characterizing the curvature of the evolution.  239 
In order to determine the drug concentration dissolved in the polymer carrier at each 240 
annealing temperature the Tg values from the annealing experiment were plotted on the 241 
Gordon-Taylor curve. In this way the solubility curve was determined (Fig. 4). The 242 
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concentration of HCT (5.6 % w/w) in the coat layer of the tablet was far below the solubility 243 
limit (31 % w/w) of HCT in the carrier. This was confirmed by the absence of the melting 244 
endotherm of HCT in the MDSC thermogram and by the absence of any peaks representative 245 
of crystalline HCT in the X-ray diffraction pattern of the extruded coat (data not shown), 246 
demonstrating HCT was present in the coat as a solid solution in the crystalline polymer 247 
mixture. MDSC thermograms of MPT-loaded core formulations showed a melting peak at 118 248 
°C. The enthalpy of fusion indicated that the main drug fraction remained crystalline in the 249 
calendered tablets: 82.3 and 85.0 % MPT was in a crystalline state in the core of formulations 250 
A and B, respectively. Similar values of MPT crystallinity were detected in the core of the mini-251 
matrices (80.0 and 85.8 % for formulations A and B, respectively), indicating that the 252 
calendering step did not affect the solid state properties of MPT. The X-ray diffraction pattern 253 
of the core of the calendered tablet also revealed diffraction peaks of MPT, confirming that the 254 
crystalline state of MPT was at least partially maintained in the tablets. Moreover, the X-ray 255 
diffractogram did not reveal differences between the cores of calendered tablets and co-256 
extruded mini-matrices (data not shown). The pore structure of the core in both dosage forms, 257 
calendered tablets and mini-matrices, was compared using micro-CT. The percentage of 258 
internal pores was 4.00 % and 1.08 % for the core of the mini-matrices and calendered tablets, 259 
respectively. The lower amount of internal pores in the calendered tablet can be attributed to 260 
the additional densification of the material during calendering. In addition, the internal pores in 261 
the calendered tablet were smaller in size: an average structure thickness of 17 ± 20 µm, in 262 
comparison to 83 ± 5 µm for the mini-matrix (Fig. 5). However, these limited differences in 263 
number and size of the internal pore structure are unlikely to have an impact on drug release. 264 
The difference in sustained release of MPT between the monolithic calendered tablets and the 265 
multiparticulates is illustrated in Figure 6. The MPT burst release was reduced by half for all 266 
calendered formulations in comparison with the mini-matrices. Moreover, the monolithic 267 
calendered tablet sustained MPT release to a larger extent than the mini-matrices, with a 268 
complete release after only 24 h instead of 8 h in case of formulation A. The lower mass 269 
transport rates from the calendered tablets were linked to the dimensions of the dosage forms: 270 
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the core of the calendered tablet had a diameter of 7 mm and a thickness of 4 mm, whereas 271 
the core of the mini-matrices had a diameter of 3 mm and a length of 2 mm. The importance 272 
of relative surface area available highlighted the importance of diffusion path length for MPT 273 
dissolution from the matrices and was confirmed by performing dissolution tests on cylindrical 274 
extrudates with a similar surface area/volume ratio to the calendered tablet and on a central 275 
part of the calendered tablet with the same dimensions as the mini-matrices. Both test set-ups 276 
indicated that the diffusion path length is the main contributor for the differences in release 277 
profiles observed between the calendered tablets and the multiparticulate formulation. Based 278 
on the release data it is evident that manufacturing an easily swallowable tablet-shaped 279 
monolithic dosage form offered an advantage over the multiparticulate formulation for 280 
sustained drug release. For the calendered formulation B, with 5 % PEO and 30 % drug 281 
content, MPT release after 48 h was only 75 %. In contrast, complete drug release from 282 
formulation C (containing 20 % PEO and 15 % MPT) was obtained after 48 h (Fig. 6). These 283 
differences in release profiles indicated that PEO was the main contributor for drug release. 284 
Because of the smaller dimensions of the mini-matrices, the matrix effect was of lesser 285 
importance for MPT release from the multiparticulates. The type of dosage form did not 286 
influence the immediate release profile of HCT, with a complete release within 45 min for all 287 
formulations (Fig. 7). To assess the impact of cooling during calendering (essential to avoid 288 
sticking of the dosage form to the rolls), the effect of the cooling rate on MPT release from the 289 
calendered tablets was determined. Cooling was performed via quench-cooling in liquid 290 
nitrogen or via cooling at room temperature. However, the MPT release profiles were 291 
independent of the cooling technique. Moreover, X-ray diffractograms of the extrudates of 292 
formulations A and B demonstrated that cooling rate did not affect crystallinity of MPT in these 293 
formulations (Fig. 8).  294 
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4. CONCLUSION 295 
In this study we have demonstrated that calendering is a promising downstream processing 296 
step to continuously produce tablet-shaped monolithic FDC dosage forms from multi-layered 297 
matrix co-extrudates. With the calendered tablet an in vitro MPT release was sustained over 298 
24 to 48 h, in combination with an immediate HCT release from the coat. The differences in 299 
diffusion path length of the final monolithic tablet-shaped dosage form mainly determined the 300 
MPT release from the core. Calendering and cooling did not affect the sustained MPT release 301 
profiles. A limited reduction of the porosity of the core after calendering indicated some 302 
additional densification of the material during calendering. The shaping technique did not alter 303 
the solid state of the drugs. Further characterization using TPI revealed a gradient in coat 304 
thickness and incomplete adhesion between core and coat, the latter being inherent to the co-305 
extrudate and independent of the calendering step, as visualized by micro-CT. This implied 306 
that at the present stage of development calendering is promising to shape FDC dosage forms 307 
with an immediate release coat, but when a sustained or extended release coat needs to be 308 
applied the technique is not an adequate solution.  309 
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Tables  369 
Table 1. Composition of calendered formulations A, B and C.  370 
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Table 1. Composition of calendered formulations A, B and C. 371 
  Matrix composition (%) Drug load (%) 
Formulation A Core EC 53 DBS 27 PEO 1M 20 MPT 30 
 Coat PEO100K 85 PEG 4K 15 HCT 5.6 
Formulation B Core EC 62 DBS 33 PEO 1M 5 MPT 30 
 Coat PEO100K 85 PEG 4K 15 HCT 5.6 
Formulation C Core EC 53 DBS 27 PEO 1M 20 MPT 15 
 Coat PEO100K 85 PEG 4K 15 HCT 2.8 
  372 
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Figures  373 
Fig. 1. Cross-section (left) and side-view (right) of a calendered tablet, with a sustained release 374 
core and an immediate release coat. 375 
Fig. 2. False-colour images, showing spatial distribution, and histograms of coating thickness 376 
for coat layer and for the air gap between core and coating layer, of the calendered tablet 377 
formulation B, analysed both at top and bottom of the tablet. 378 
Fig. 3. Micro-CT image of a string of calendered tablets, were the recurrent thinner part of the 379 
coat layer is indicated with an arrow, and detail of the calendered tablet for formulation B. 380 
Fig. 4. Evolution of glass transition temperature, fitted with a Gordon-Taylor law ( ) and 381 
solubility curve (   ) for HCT in the PEO/PEG carrier.   382 
Fig. 5. Pore size distributions of internal pores for mini-matrix ( ) and calendered tablet ( ), 383 
analysed on a reconstructed micro-CT image. 384 
Fig. 6. In vitro MPT release (in phosphate buffer pH 6.8) from calendered tablets (open 385 
symbols) and mini-matrices (closed symbols) for formulation A  (circle), formulation B (square), 386 
formulation C (triangle). Mean (n = 3) dissolution profiles (± SD) of co-extrudates.  387 
Fig. 7. Mean in vitro HCT release (in HCl 0.1 N) from calendered tablets (open symbols) and 388 
mini-matrices (closed symbols) for formulations A to C. Mean (n = 3) dissolution profiles (± SD) 389 
of co-extrudates. 390 
Fig. 8. X-ray diffraction patterns of extruded core. MPT (1), formulation B cooled at room 391 
temperature (2) or quench-cooled in liquid nitrogen (3), formulation A cooled at room 392 
temperature (4) or quench-cooled in liquid nitrogen (5).  393 
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Fig. 1. Cross-section (left) and side-view (right) of a calendered tablet, with a sustained release 394 
core and an immediate release coat.  395 
25 
 
Fig. 2. False-colour images, showing spatial distribution, and histograms of coating thickness 396 
for coat layer and for the air gap between core and coating layer, of the calendered tablet 397 
formulation B, analysed both at top and bottom of the tablet. 398 
 399 
  400 
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Fig. 3. Micro-CT image of a string of calendered tablets, where the recurrent thinner part of 401 
the coat layer is indicated with an arrow, and detail of the calendered tablet for formulation B. 402 
403 
 404 
405 
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Fig. 4. Evolution of glass transition temperature, fitted with a Gordon-Taylor law ( ) and 406 
solubility curve (   ) for HCT in the PEO/PEG carrier.  407 
 408 
  409 
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Fig. 5. Pore size distributions of internal pores for mini-matrix ( ) and calendered tablet ( ), 410 
analysed on a reconstructed micro-CT image. 411 
0 50 100 150 200 250
0
10
20
30
40
50
60
70
Mid-range structure thickness (µm)
%
 in
te
rn
al
 p
or
es
 in
 r
an
ge
 412 
413 
29 
 
Fig. 6. In vitro MPT release (in phosphate buffer pH 6.8) from calendered tablets (open 414 
symbols) and mini-matrices (closed symbols) for formulation A  (circle), formulation B (square), 415 
formulation C (triangle). Mean (n = 3) dissolution profiles (± SD) of co-extrudates.  416 
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Fig. 7. Mean in vitro HCT release (in HCl 0.1 N) from calendered tablets (open symbols) and 419 
mini-matrices (closed symbols) for formulations A to C. Mean (n = 3) dissolution profiles (± SD) 420 
of co-extrudates. 421 
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Fig. 8. X-ray diffraction patterns of MPT (1), extruded core formulation B cooled at room 424 
temperature (2) or quench-cooled in liquid nitrogen (3), extruded core formulation A cooled at 425 
room temperature (4) or quench-cooled in liquid nitrogen (5). 426 
 427 
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